Treatment of moderate to severe restless legs syndrome: 2-year safety and efficacy of rotigotine transdermal patch

Treatment of moderate to severe restless legs syndrome: 2-year safety and efficacy of rotigotine transdermal patch

<p>Abstract</p> <p>Background</p> <p>Rotigotine is a unique dopamine agonist with activity across D1 through D5 receptors as well as select adrenergic and serotonergic sites. This study reports the 2-year follow-up safety and efficacy data of an ongoing open-label multi...

Full description

Bibliographic Details
Main Authors: Trenkwalder Claudia, García-Borreguero Diego, Beneš Heike, Geisler Peter, Stiasny-Kolster Karin, Oertel Wolfgang H, Högl Birgit, Poewe Werner, Schollmayer Erwin, Kohnen Ralf
Format: Article
Language:English
Published: BMC 2010-09-01
Series:BMC Neurology
Online Access:http://www.biomedcentral.com/1471-2377/10/86

Internet

http://www.biomedcentral.com/1471-2377/10/86

Similar Items